Virax Biolabs Group Ltd SEC filings VRAX

Virax Biolabs Group Ltd has 159 filings in SEC EDGAR's recent list, going back to Dec 27, 2021. Its latest annual report, Form 20-F, was filed on Jul 6, 2026 for the period ended Mar 31, 2026. The most recent current report (Form 6-K) was filed on Oct 29, 2026. The company's fiscal year ends on March 31.

Form Description Filed Period
6-K Current report (foreign issuer) Oct 29, 2026 Oct 29, 2026
6-K Current report (foreign issuer) Oct 9, 2026 Oct 9, 2026
6-K Current report (foreign issuer) Sep 4, 2026 Sep 4, 2026
6-K Current report (foreign issuer) Aug 26, 2026 Aug 21, 2026
6-K Current report (foreign issuer) Aug 18, 2026 Aug 18, 2026
6-K Current report (foreign issuer) Jul 31, 2026 Jul 31, 2026
6-K Current report (foreign issuer) Jul 16, 2026 Jul 16, 2026
6-K Current report (foreign issuer) Jul 10, 2026 Jul 10, 2026
6-K Current report (foreign issuer) Jul 9, 2026 Jul 9, 2026
6-K Current report (foreign issuer) Jun 24, 2026 Jun 24, 2026
6-K Current report (foreign issuer) Jun 12, 2026 Jun 12, 2026
6-K Current report (foreign issuer) May 26, 2026 May 26, 2026
6-K Current report (foreign issuer) May 22, 2026 May 22, 2026
6-K Current report (foreign issuer) Apr 14, 2026 Apr 14, 2026
6-K Current report (foreign issuer) Apr 10, 2026 Apr 10, 2026
6-K Current report (foreign issuer) Mar 18, 2026 Mar 18, 2026
6-K Current report (foreign issuer) Jan 30, 2026 Jan 30, 2026
6-K Current report (foreign issuer) Dec 4, 2025 Dec 4, 2025
6-K Current report (foreign issuer) Dec 2, 2025 Dec 2, 2025
6-K Current report (foreign issuer) Jul 30, 2025 Jul 30, 2025
6-K Current report (foreign issuer) Jun 13, 2025 Jun 13, 2025
6-K Current report (foreign issuer) Mar 18, 2025 Mar 18, 2025
6-K Current report (foreign issuer) Mar 13, 2025 Mar 13, 2025
6-K Current report (foreign issuer) Mar 5, 2025 Mar 5, 2025
6-K Current report (foreign issuer) Feb 25, 2025 Feb 25, 2025
6-K Current report (foreign issuer) Dec 23, 2024 Dec 23, 2024
6-K Current report (foreign issuer) Dec 17, 2024 Dec 17, 2024
6-K Current report (foreign issuer) Dec 10, 2024 Dec 10, 2024
6-K Current report (foreign issuer) Nov 20, 2024 Nov 20, 2024
6-K Current report (foreign issuer) Oct 31, 2024 Oct 31, 2024
6-K Current report (foreign issuer) Oct 23, 2024 Oct 23, 2024
6-K Current report (foreign issuer) Sep 30, 2024 Sep 30, 2024
6-K Current report (foreign issuer) Aug 23, 2024 Aug 23, 2024
6-K Current report (foreign issuer) Jun 11, 2024 Jun 11, 2024
6-K Current report (foreign issuer) Apr 25, 2024 Apr 25, 2024
6-K Current report (foreign issuer) Apr 16, 2024 Apr 16, 2024
6-K Current report (foreign issuer) Mar 15, 2024 Mar 15, 2024
6-K Current report (foreign issuer) Jan 22, 2024 Jan 22, 2024
6-K Current report (foreign issuer) Jan 12, 2024 Jan 11, 2024
6-K Current report (foreign issuer) Dec 21, 2023 Dec 21, 2023
6-K Current report (foreign issuer) Dec 20, 2023 Dec 20, 2023
6-K Current report (foreign issuer) Dec 18, 2023 Dec 18, 2023
6-K Current report (foreign issuer) Dec 14, 2023 Dec 14, 2023
6-K Current report (foreign issuer) Dec 8, 2023 Dec 8, 2023
6-K Current report (foreign issuer) Nov 8, 2023 Nov 8, 2023
6-K Current report (foreign issuer) Oct 31, 2023 Oct 31, 2023
6-K Current report (foreign issuer) Oct 12, 2023 Oct 12, 2023
6-K Current report (foreign issuer) Oct 4, 2023 Oct 4, 2023
6-K Current report (foreign issuer) Sep 12, 2023 Sep 12, 2023
6-K Current report (foreign issuer) Sep 1, 2023 Sep 1, 2023
6-K Current report (foreign issuer) Aug 3, 2023 Aug 3, 2023
6-K Current report (foreign issuer) Jul 18, 2023 Jul 18, 2023
6-K Current report (foreign issuer) Jun 14, 2023 Jun 14, 2023
6-K Current report (foreign issuer) May 4, 2023 May 4, 2023
6-K Current report (foreign issuer) Apr 21, 2023 Apr 21, 2023
6-K Current report (foreign issuer) Apr 19, 2023 Apr 19, 2023
6-K Current report (foreign issuer) Mar 10, 2023 Mar 10, 2023
6-K Current report (foreign issuer) Mar 7, 2023 Mar 7, 2023
6-K Current report (foreign issuer) Feb 7, 2023 Feb 7, 2023
6-K Current report (foreign issuer) Feb 2, 2023 Feb 2, 2023
6-K Current report (foreign issuer) Feb 2, 2023 Feb 2, 2023
6-K Current report (foreign issuer) Jan 4, 2023 Jan 4, 2023
6-K Current report (foreign issuer) Dec 6, 2022 Dec 6, 2022
6-K Current report (foreign issuer) Nov 18, 2022 Nov 18, 2022
6-K Current report (foreign issuer) Nov 15, 2022 Nov 15, 2022
6-K Current report (foreign issuer) Nov 8, 2022 Nov 8, 2022
6-K Current report (foreign issuer) Nov 3, 2022 Nov 3, 2022
6-K Current report (foreign issuer) Oct 26, 2022 Oct 26, 2022
6-K Current report (foreign issuer) Sep 22, 2022 Sep 22, 2022
6-K Current report (foreign issuer) Sep 20, 2022 Sep 20, 2022
6-K Current report (foreign issuer) Sep 12, 2022 Sep 12, 2022
6-K Current report (foreign issuer) Sep 7, 2022 Sep 7, 2022
6-K Current report (foreign issuer) Jul 29, 2022 Jul 29, 2022
6-K Current report (foreign issuer) Jul 26, 2022 Jul 26, 2022

Showing 74 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as
VRAX (Nasdaq)
Fiscal year ends
March 31
Incorporated in
Cayman Islands
Headquarters
Lanarkshire, United Kingdom
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1885827
Former names
Virax Biolabs (Cayman) Ltd (until Dec 27, 2021)

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.